Persistent Poor Metabolic Profile in Postmenopausal Women With Ovarian Hyperandrogenism After Testosterone Level Normalization

Imagem de Miniatura
Arquivos
art_ROCHA_Persistent_Poor_Metabolic_Profile_in_Postmenopausal_Women_With_2019.PDF (364.57 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2019
Editora
ENDOCRINE SOC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
YANCE, Viviane V. R.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF THE ENDOCRINE SOCIETY, v.3, n.5, p.1087-1096, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Context: Data on prevalence of metabolic risk factors in hyperandrogenic postmenopausal women are limited. Also, the correlation between metabolic disorders and androgen excess in this scenario is poorly understood. Objectives: We aimed to assess the prevalence of obesity, hypertension, type 2 diabetes (T2D), and dyslipidemia (DLP) in postmenopausal women with hyperandrogenism of ovarian origin before and after surgical normalization of testosterone (T) levels, as well as the impact of androgen normalization on body mass index (BMI), glucose, and lipid metabolism. Design: Retrospective study. Setting: Tertiary health center. Participants: Twenty-four Brazilian women with postmenopausal hyperandrogenism who underwent bilateral oophorectomy between 2004 and 2014 and had histologically confirmed virilizing ovarian tumor (VOT) or ovarian hyperthecosis (OH) and T-level normalization after surgery were selected. Main Outcome Measures: FSH, LH, total and calculated free T, BMI, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) serum levels were accessed before (n = 24) and 24 months after (n 5 19) bilateral oophorectomy. Results: At baseline, the overall prevalence rates of obesity, T2D, DLP, and hypertension were 58.3%, 83.3%, 66.7%, and 87.5%, respectively. No significant difference in prevalence was found between patients with OH and VOTs. At follow-up, FSH, LH, and total and free T levels had returned to menopausal physiologic levels, but mean BMI and mean FPG, HbA1c, LDL-C, HDL-C, and TG levels did not differ from baseline. Conclusions: Postmenopausal hyperandrogenism is associated with adverse metabolic risk. Longterm normalization of testosterone levels did not improve BMI, glucose, or lipid metabolism.
Palavras-chave
postmenopausal hyperandrogenism, ovarian hyperthecosis, virilizing ovarian tumor, metabolic risk factors
URI
https://observatorio.fm.usp.br/handle/OPI/33129
Referências
  1. Al-Ozairi E, 2008, INT J GYNECOL OBSTET, V100, P280, DOI 10.1016/j.ijgo.2007.08.017
  2. Azziz R, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.57
  3. Barth JH, 1997, CLIN ENDOCRINOL, V46, P123, DOI 10.1046/j.1365-2265.1997.1050916.x
  4. Castell AL, 2012, GYNECOL OBSTET FERTI, V40, P316, DOI 10.1016/j.gyobfe.2011.07.049
  5. Crespo RP, 2018, ARCH ENDOCRIN METAB, V62, P352, DOI 10.20945/2359-3997000000049
  6. Diamond MP, 1998, J CLIN ENDOCR METAB, V83, P4420, DOI 10.1210/jc.83.12.4420
  7. Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098
  8. Golden SH, 2004, AM J EPIDEMIOL, V160, P540, DOI 10.1093/aje/kwh250
  9. HATCH R, 1981, AM J OBSTET GYNECOL, V140, P815, DOI 10.1016/0002-9378(81)90746-8
  10. Horejsi J, 1997, ANN NY ACAD SCI, V816, P369
  11. KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401
  12. KHAW KT, 1991, CLIN SCI, V80, P199, DOI 10.1042/cs0800199
  13. Laughlin GA, 2010, J CLIN ENDOCR METAB, V95, P740, DOI 10.1210/jc.2009-1693
  14. Lu Zhaohui, 2014, Zhonghua Bing Li Xue Za Zhi, V43, P649
  15. LUDWIG E, 1977, BRIT J DERMATOL, V97, P247, DOI 10.1111/j.1365-2133.1977.tb15179.x
  16. Moghetti P, 1996, J CLIN ENDOCR METAB, V81, P952, DOI 10.1210/jc.81.3.952
  17. MORGAN LS, 1990, SEMIN SURG ONCOL, V6, P83, DOI 10.1002/ssu.2980060206
  18. Nagamani M, 1999, J CLIN ENDOCR METAB, V84, P1685, DOI 10.1210/jc.84.5.1685
  19. NESTLER JE, 1991, J CLIN ENDOCR METAB, V72, P83, DOI 10.1210/jcem-72-1-83
  20. O'Reilly MW, 2017, J CLIN ENDOCR METAB, V102, P3327, DOI 10.1210/jc.2017-00947
  21. O'Reilly MW, 2014, J CLIN ENDOCR METAB, V99, P1027, DOI 10.1210/jc.2013-3399
  22. Oh JY, 2002, DIABETES CARE, V25, P55, DOI 10.2337/diacare.25.1.55
  23. Patel SM, 2010, FERTIL STERIL, V94, P2161, DOI 10.1016/j.fertnstert.2010.01.064
  24. Patel SM, 2009, J CLIN ENDOCR METAB, V94, P4776, DOI 10.1210/jc.2009-0740
  25. Pelusi C, 2013, CLIN ENDOCRINOL, V78, P533, DOI 10.1111/j.1365-2265.2012.04438.x
  26. Phillips GB, 2000, DIABETES CARE, V23, P74, DOI 10.2337/diacare.23.1.74
  27. POLDERMAN KH, 1994, J CLIN ENDOCR METAB, V79, P265, DOI 10.1210/jc.79.1.265
  28. Rincon J, 1996, DIABETES, V45, P615, DOI 10.2337/diabetes.45.5.615
  29. Schmidt MI, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-123
  30. Selvaggi SM, 2000, ARCH PATHOL LAB MED, V124, P477
  31. Vaikkakara S, 2008, GYNECOL ENDOCRINOL, V24, P87, DOI 10.1080/09513590701807100
  32. Vigitel Brazil, 2016, VIG BRAZ 2016 SURV R

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/42
Carregar mais